reports
Epsilon Energy Ltd. Announces the Divestment of Dewey Energy Holdings ...
Epsilon Energy Ltd. Announces the Divestment of Dewey Energy Holdings LLC and the Company’s Asset in the Anadarko Basin HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced the signing of definitive transaction documents and the coincident closing of a sale of the Company’s wholly owned subsidiary, Dewey Energy Holdings, LLC, which holds the Company’s Western Anadarko basin assets, to an undisclosed private buyer. The assets sold included approximately 813 Mcfe/d (60% natural gas) of production (Q3 2025 figure) and app...
Clene to Present at the Emerging Growth Conference
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: December 10, 2025Time of Pr...
Clene Announces Statistically Significant ALS Biomarker Results Suppor...
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today...
Clene to Provide CNM-Au8® ALS Program Update
Clene to Provide CNM-Au8® ALS Program Update Webcast set for 8:30 a.m. ET on December 3rd SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wedn...
Epsilon Energy Ltd. Announces Quarterly Dividend
Epsilon Energy Ltd. Announces Quarterly Dividend HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the shareholders of record at the close of business on December 15, 2025, payable on December 31, 2025. All dividends paid by the Company are “eligible dividends” as defined in subsection 89(1) of the Income Tax Act (Canada), unless indicated otherwise. About Epsilon Epsilon Energy Ltd. is a North American...
Epsilon Announces the Issuance of Contingent Shares as Consideration f...
Epsilon Announces the Issuance of Contingent Shares as Consideration for the Acquisition of Peak BLM Lease LLC HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the issuance of common shares as consideration in connection with the acquisition of Peak BLM Lease LLC, which closed on November 14, 2025. As contemplated by the membership interest purchase agreement for Peak BLM Lease LLC (“Purchase Agreement”), a copy of which was attached to the Company’s proxy statement filed with the Securities and Exchange Commission ...
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One...
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Inv...
Epsilon Announces the Closing of the Acquisitions of the Peak Companie...
Epsilon Announces the Closing of the Acquisitions of the Peak Companies With Assets in the Powder River Basin HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the consummation of the previously announced acquisitions of Peak Exploration and Production LLC and Peak BLM Lease LLC (together, the “Peak Companies”) (the “Closing”). The Closing followed a special meeting of the Company’s shareholders held on November 12, 2025, where the Company’s shareholders approved the issuance of common shares in connection with the a...
Clene Reports Third Quarter 2025 Financial Results and Recent Operatin...
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analysesThe Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathwayThe Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026The FDA and ...
Epsilon Announces Third Quarter 2025 Results
Epsilon Announces Third Quarter 2025 Results HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported third quarter 2025 financial and operating results. Third Quarter 2025 Highlights: Epsilon - Q3 2025 Q3 2025Q2 2025Q3 2024QoQ%YoY%YTD 2025NRI Production GasMMcf2,1362,7521,304-22%64%7,628OilMbbl394453-11%-26%129NGLMbbl1481778%-18%38TotalMmcfe2,4563,0641,727-20%42%8,629DailyMmcfe/d26.733.718.8 31.6 Revenues$M Gas 4,7586,9101,904-31%150%22,282Oil 2,5112,7253,965-8%-37%8,505NGL 26714533584%-20%799Mid...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
FDS FACTSET RESEARCH SYSTEMS INC.
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
CMC COMMERCIAL METALS COMPANY
CAPL CROSSAMERICA PARTNERS LP
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
ATRO ASTRONICS CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
GRF EAGLE CAPITAL GROWTH FUND INC
GWRS GLOBAL WATER RESOURCES
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
STRO CPS TECHNOLOGIES
GRX SUTRO BIOPHARMA
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PCB PENNANT GROUP
WWR PACIFIC CITY FINANCIAL CORP
ACET WESTWATER RESOURCES
CGEM ADICET BIO INC
SMMT CULLINAN ONCOLOGY INC
INTA SUMMIT THERAPEUTICS INC
IMRX INTAPP INC
REFI IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
EP VIVANI MEDICAL INC
SOC EMPIRE PETROLEUM CORP
LAW SABLE OFFSHORE CORP
HYMC CS DISCO INC
NUGN HYCROFT MINING HOLDING CORPORATION
LIVENTO GROUP
INC.
Epsilon Energy Ltd. Schedules Third Quarter 2025 Earnings Release and ...
Epsilon Energy Ltd. Schedules Third Quarter 2025 Earnings Release and Conference Call HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its third quarter 2025 earnings release on Wednesday, November 5, 2025 after the market close and host a conference call to discuss its financial and operating results on Thursday, November 6, 2025 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. Internatio...
FB Financial Corp: 1 director
A director at FB Financial Corp bought 9,147 shares at 54.674USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Jonathan Moreland
Clene to Present at the Emerging Growth Conference
Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: October 23, 2025Time of Pre...
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Clene to Participate in a Panel Discussion at the Maxim Growth Summit SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor mee...
Epsilon Announces New and Revised Senior Secured Reserve-Based Revolvi...
Epsilon Announces New and Revised Senior Secured Reserve-Based Revolving Credit Facility HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported the closing of a new and revised senior secured reserve-based revolving credit facility (the “Credit Facility”) with Frost Bank as the administrative agent and Frost Bank and Texas Capital Bank as lenders. The new Credit Facility replaces the Company’s previous credit facility. Term highlights of the Credit Facility: Epsilon Energy USA Inc. and Epsilon Energy Ltd. as co-borrowers...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CNM-Au8® improved the brain’s energy metabolism evidenced by improved NAD+/NADH ratio At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligne...
Epsilon Energy Ltd. Announces Quarterly Dividend
Epsilon Energy Ltd. Announces Quarterly Dividend HOUSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the stock holders of record at the close of business on September 15, 2025, payable on September 30, 2025. All dividends paid by the Company are “eligible dividends” as defined in subsection 89(1) of the Income Tax Act (Canada), unless indicated otherwise. About Epsilon Epsilon Energy Ltd. is a North Amer...
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment ...
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease Results presented today at the H2 Therapeutics Stewardship Meeting in New York City, hosted by the Michael J Fox Foundation Taken together with results from a Phase 2 study that demonstrated orally dosed CNM-Au8 favorably alters cri...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.